These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 24955573

  • 1. Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons.
    Verdecchia P, Angeli F, Lip GY, Reboldi G.
    PLoS One; 2014; 9(6):e100478. PubMed ID: 24955573
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Skjøth F, Larsen TB, Rasmussen LH, Lip GY.
    Thromb Haemost; 2014 May 05; 111(5):981-8. PubMed ID: 24577485
    [Abstract] [Full Text] [Related]

  • 3. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY, Mitchell SA, Liu X, Liu LZ, Phatak H, Kachroo S, Batson S.
    Int J Cardiol; 2016 Feb 01; 204():88-94. PubMed ID: 26655548
    [Abstract] [Full Text] [Related]

  • 4. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
    Sardar P, Chatterjee S, Lavie CJ, Giri JS, Ghosh J, Mukherjee D, Lip GY.
    Int J Cardiol; 2015 Jan 20; 179():279-87. PubMed ID: 25464465
    [Abstract] [Full Text] [Related]

  • 5. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
    Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J.
    J Med Econ; 2012 Jan 20; 15(4):776-85. PubMed ID: 22449118
    [Abstract] [Full Text] [Related]

  • 6. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
    Kanai Y, Oguro H, Tahara N, Matsuda H, Takayoshi H, Mitaki S, Onoda K, Yamaguchi S.
    J Stroke Cerebrovasc Dis; 2018 Feb 20; 27(2):338-345. PubMed ID: 29033229
    [Abstract] [Full Text] [Related]

  • 7. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
    Kakkos SK, Kirkilesis GI, Tsolakis IA.
    Eur J Vasc Endovasc Surg; 2014 Nov 20; 48(5):565-75. PubMed ID: 24951377
    [Abstract] [Full Text] [Related]

  • 8. Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
    Weitz JI, Eikelboom J.
    Thromb Haemost; 2016 Jan 20; 115(2):257-70. PubMed ID: 26466666
    [Abstract] [Full Text] [Related]

  • 9. [Evidence of novel oral anticoagulants (NOAC)].
    Kitazono T.
    Rinsho Shinkeigaku; 2013 Jan 20; 53(11):992-3. PubMed ID: 24291856
    [Abstract] [Full Text] [Related]

  • 10. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S, Katada J, Saito K, Jenkins A, Li B, Mardekian J, Terayama Y.
    Open Heart; 2020 Jan 20; 7(1):e001232. PubMed ID: 32341789
    [Abstract] [Full Text] [Related]

  • 11. Perioperative management of patients on new oral anticoagulants.
    Lai A, Davidson N, Galloway SW, Thachil J.
    Br J Surg; 2014 Jun 20; 101(7):742-9. PubMed ID: 24777590
    [Abstract] [Full Text] [Related]

  • 12. Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
    Messori A, Fadda V, Maratea D, Trippoli S, Marinai C.
    Int J Clin Pharmacol Ther; 2015 Mar 20; 53(3):211-9. PubMed ID: 25295718
    [Abstract] [Full Text] [Related]

  • 13. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Vargas-Castrillón E.
    Thromb Res; 2014 Oct 20; 134(4):774-82. PubMed ID: 25037495
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
    van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV.
    J Thromb Haemost; 2014 Oct 20; 12(3):320-8. PubMed ID: 24330006
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article.
    Liu X, Huang M, Ye C, Zeng J, Zeng C, Ma J.
    Medicine (Baltimore); 2020 Jul 02; 99(27):e21025. PubMed ID: 32629725
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.